VX-809

• CAT Number: I005566
• CAS Number: 936727-05-8
• Molecular Formula: C24H18F2N2O5
• Molecular Weight: 452.41
• Purity: ≥95%
• Synonyms: VX809;VX 809
• Target: Autophagy
• Solubility: 10 mM in DMSO
• Storage: store at -20℃
• IC50: 0.1 uM (EC50)
• IUPAC Name: 3-[6-[[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropanecarbonyl]amino]-3-methylpyridin-2-yl]benzoic acid
• InChI: InChI=1S/C24H18F2N2O5/c1-13-5-8-19(27-20(13)14-3-2-4-15(11-14)21(29)30)28-22(31)23(9-10-23)16-6-7-17-18(12-16)33-24(25,26)32-17/h2-8,11-12H,9-10H2,1H3,(H,29,30)(H,27,28,31)
• InChIKey: UFSKUSARDNFIRC-UHFFFAOYSA-N
• SMILES: CC1=C(N=C(C=C1)NC(=O)C2(CC2)C3=CC4=C(C=C3)OC(O4)(F)F)C5=CC(=CC=C5)C(=O)O

VX-809（Cat No.:I005566）, also known as lumacaftor, is a drug developed to treat cystic fibrosis (CF) caused by the F508del mutation in the CFTR gene. It functions as a CFTR corrector, aiming to improve the processing and trafficking of the defective CFTR protein to the cell surface. By enhancing the protein’s function, VX-809 helps alleviate symptoms such as difficulty breathing and lung infections. It is typically used in combination with ivacaftor (VX-770) to boost the overall effectiveness of CF treatment. VX-809 has shown significant improvements in lung function and quality of life in CF patients.